FDA starts review of Roche's Gazyva in lupus nephritis

Roche's anti-CD20 antibody Gazyva has been on the market for more than a decade as a treatment for blood cancer, but could see a new lease of life if it gets FDA approval to treat kidney disease caused by the autoimmune disorder systemic lupus erythematosus (SLE).